Name: Latest research reports of Natco Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Natco Pharma Ltd.
Rating: 5
Author: ICICI Securities Limited

Stunted recovery mars performance

Buy: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco Pharma’s (Natco) Q2FY23 performance was lower than our estimates on all fronts. Revenue grew 14.6% YoY (-51.2% QoQ) to Rs4.3bn – below our expectation of
Rs5.6bn.